SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Land Shark who wrote (19188)3/10/1999 2:58:00 PM
From: Anthony@Pacific  Read Replies (2) | Respond to of 122087
 
Thanks Yield lets wait a while..



To: Land Shark who wrote (19188)3/10/1999 3:01:00 PM
From: Cube  Respond to of 122087
 
IMCL, The difference with this company is the human trial results. 13 of 15 human patients had their head and neck tumors vanish entirely. Unlike ENMD mouseicide, IMCL will be going into phase 3 with good human results.

Cube



To: Land Shark who wrote (19188)3/10/1999 3:06:00 PM
From: Bear Down  Read Replies (2) | Respond to of 122087
 
Yields, I would be careful with IMCL. Did you hear the teaser on CNBC?? Human trials showing great results. Tumors disappearing in humans in not like shrinking them in mice. This technology is nothing even close to ENMD and their crap.

I am not a biotech genius so take this with a grain of salt but if the interview tomorrow is half what the teaser was this could be a GERN, ENMD style takeoff


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News